Alzheimer’s Drug Discovery Foundation (ADDF): Translational and Clinical Research on Alzheimer’s Disease

ADDF is interested in novel targets and therapeutic approaches for Alzheimer’s Disease (AD), related dementias and cognitive aging. ADDF funds drug discovery and preclinical development, early detection, clinical trials and prevention, but NOT basic research. These areas include, but are not limited to: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers. ADDF has limited interest in funding anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs. Funding priorities: Early identification; Prevention of AD and cognitive decline; Treatment of AD and cognitive aging.

* Preclinical Drug Discovery: Drug discovery and biomarker development.. Funding averages $150K/year. In some cases, multi-year proposals can be considered.

* Program to Accelerate Clinical Trials: Funding- up to $1.5M per application, is offered to increase the number of innovative drugs tested in humans. Program areas are: repurposing and therapies addressing targets outlined in the call.

* ADDF/NIH: financial assistance for relevant NIA and NINDS grant applications thatwere scored but not funded AND fall within the ADDF’s current funding priorities (Application deadline is rolling)

* Accelerating Drug Discovery for Frontotemporal Degeneration: priority areas: development and testing of novel high throughput screening assays, preclinical testing of novel or repurposed drug candidates, proteomics/transcriptomics/metabolomics for FTD biomarkers, functional imaging methods, neurodegeneration and differential connectivity patterns, innovate software, innovative clinical trials. Awards average $150,000-$200,000/1 year; longer duration and larger budgets will be considered.

* ADDF/Belfer ApoE Therapeutics Innovation Program: Projects aimed to accelerate the development of novel therapeutics specifically designed to target apoE pathological mechanisms. Funding up to $300,000/1-2 years.

http://www.alzdiscovery.org/research-and-grants/request-for-proposal